Skip to main content
Top

22-01-2025 | SCLC | REVIEW Free for a limited time

Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer

Authors: Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang

Published in: Current Treatment Options in Oncology

Login to get access

Opinion Statement

Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.
Literature
6.
go back to reference Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65. https://doi.org/10.1016/s1470-2045(20)30539-8.CrossRefPubMed Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65. https://​doi.​org/​10.​1016/​s1470-2045(20)30539-8.CrossRefPubMed
7.
go back to reference Liu V. Stephen, et al. Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: Imbrella a extension study results. 2023 WCLC; OA01.04. Liu V. Stephen, et al. Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: Imbrella a extension study results. 2023 WCLC; OA01.04.
12.
go back to reference Cheng Ying, et al. ASTRUM-005: Updated results of first-line serplulimab versus placebo combinated with chemotherapy in extensive-stage small-cell lung cancer. 2022 ESMO ASIA. LBA9. Cheng Ying, et al. ASTRUM-005: Updated results of first-line serplulimab versus placebo combinated with chemotherapy in extensive-stage small-cell lung cancer. 2022 ESMO ASIA. LBA9.
13.
go back to reference Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024;19:1073–85. https://doi.org/10.1016/j.jtho.2024.03.008.CrossRefPubMed Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024;19:1073–85. https://​doi.​org/​10.​1016/​j.​jtho.​2024.​03.​008.CrossRefPubMed
22.
29.
go back to reference Chung HC, Lopez-Martin JA, Kao CH, Miller WH, & Piha-Paul, SA.Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.J Clin Oncol. 2018;36:8506. Chung HC, Lopez-Martin JA, Kao CH, Miller WH, & Piha-Paul, SA.Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.J Clin Oncol. 2018;36:8506.
32.
go back to reference Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–65. https://doi.org/10.1016/s1470-2045(20)30445-9.CrossRefPubMed Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–65. https://​doi.​org/​10.​1016/​s1470-2045(20)30445-9.CrossRefPubMed
48.
go back to reference Schmälter AK, Löhr P, Konrad M, Waidhauser J, Arndt TT, Schiele S, et al. Alterations in Peripheral Lymphocyte Subsets under Immunochemotherapy in Stage IV SCLC Patients: Th17 Cells as Potential Early Predictive Biomarker for Response. Int J Mol Sci. 2024;25. https://doi.org/10.3390/ijms25105056. Schmälter AK, Löhr P, Konrad M, Waidhauser J, Arndt TT, Schiele S, et al. Alterations in Peripheral Lymphocyte Subsets under Immunochemotherapy in Stage IV SCLC Patients: Th17 Cells as Potential Early Predictive Biomarker for Response. Int J Mol Sci. 2024;25. https://​doi.​org/​10.​3390/​ijms25105056.
65.
go back to reference Ohe Yuichiro, Han Baohui, Nishio Makoto, Watanabe Satoshi, Ren Xiubao, Murakami Shuji, Yang Nong et al. BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. 2024 ASCO Annual Meeting Abstract: 8001. Ohe Yuichiro, Han Baohui, Nishio Makoto, Watanabe Satoshi, Ren Xiubao, Murakami Shuji, Yang Nong et al. BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. 2024 ASCO Annual Meeting Abstract: 8001.
Metadata
Title
Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer
Authors
Yili Shen
Zhicong Liu
Yi Chen
Xuefei Shi
Shunli Dong
Bin Wang
Publication date
22-01-2025
Publisher
Springer US
Published in
Current Treatment Options in Oncology
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-025-01292-x

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now